Sign In
Buy EDSA
$5.11
-0.140 (-2.67%)
At Close: Jul 31, 2026
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
08:00am, Tuesday, 19'th Oct 2021
Mortality reductions demonstrated across multiple patient groups Additional efficacy signals recorded in a broad range of mild to severe ARDS patients Company to focus on critically ill population for
Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
02:57pm, Wednesday, 22'nd Sep 2021
On Sep 20, EDSA reports positive p2 data. On a request of the DSMB (Data and Safety Monitoring Board), p2 portion of EDSA's ongoing p2/3 trial was "preemptively unblinded".
EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday
04:28pm, Monday, 20'th Sep 2021
Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride. The post EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Mo
Why Edesa Biotech Shares Are Soaring Today
02:43pm, Monday, 20'th Sep 2021
Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients dem
How To Play Edsa Biotech's Stock After 60% Surge
01:55pm, Monday, 20'th Sep 2021
Edsa Biotech Inc. (NASDAQ:EDSA) shares are trading higher after the company announced Phase 2 Data of its Monoclonal Antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a
EDSA Stock: Why It Significantly Increased Today
08:27am, Monday, 20'th Sep 2021
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 60% pre-market. This is why it happened.
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
08:00am, Monday, 20'th Sep 2021
Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care Dat
Edesa Biotech Provides Update For COVID-19 Antibody Trial
01:01pm, Thursday, 26'th Aug 2021
Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for hospitalized COVID-19 patients. Edesa report
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
07:30am, Thursday, 26'th Aug 2021
Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter TORO
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
07:50am, Friday, 13'th Aug 2021
TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial
Edesa Biotech Extends Dermatitis Study to Canada
08:10am, Tuesday, 13'th Jul 2021
TORONTO, ON / ACCESSWIRE / July 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the c
EDSA Stock Price Increases Over 14% Pre-Market: Why It Happened
08:17am, Friday, 18'th Jun 2021
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 14% pre-market. This is why it happened.
Edesa Biotech Reports Favorable Review of COVID-19 Study
07:45am, Friday, 18'th Jun 2021
TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an ind
Edesa Biotech to Attend BIO Digital 2021
08:00am, Tuesday, 08'th Jun 2021
TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the co
Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial
08:47am, Thursday, 03'rd Jun 2021
Edesa Biotech Inc's (NASDAQ: EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy for moderate to severe chronic Allergic Contact
